4.00Open4.00Pre Close0 Volume2 Open Interest15.00Strike Price0.00Turnover1690.77%IV163.89%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry4.00Extrinsic Value100Contract SizeAmericanOptions Type0.7351Delta0.0228Gamma1.80Leverage Ratio-0.5101Theta0.0002Rho1.32Eff Leverage0.0028Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet